Mode
Text Size
Log in / Sign up
N/A N=118 Diagnostic

Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility

Lung Disease

Enrolled (actual)
118
Serious AEs
81.4%
Results posted
Oct 2020
Primary outcome: Primary: Count of Participants With Primary Graft Dysfunction (PGD), Grade 3 — 8; 8; 2 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Toronto EVLP System™ (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Lung Bioengineering Inc.
Primary completion
Nov 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Count of Participants With Primary Graft Dysfunction (PGD), Grade 3
8; 8; 2
PRIMARY
Count of Participants Surviving
35; 31; 52
SECONDARY
PGD Score
8; 8; 2; 8; 7; 3
SECONDARY
ICU Length of Stay
17.0; 9.0; 5.0
SECONDARY
Total Lung Preservation Time (TPT)
13.4; 12.2; 3.0
SECONDARY
Time to First Extubation
78.1; 31.1; 21.5
SECONDARY
Hospital Length of Stay
36.0; 19.0; 18.0

Summary

This is a safety study to compare the safety of receiving a lung treated with the Toronto EVLP System™ by SPONSOR in SPONSOR's dedicated facility against standard lung transplantation.

Eligibility Criteria

Subject Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Male or female patients
  • All patients, 18 years of age or older
  • Patient already on or added to the active waiting list for a single or bilateral lung transplant
  • Patient or patient's representative provides informed consent for participation in the study at the time of study commencement or time of listing for transplant
  • Patient or patient's representative reconfirms informed consent for the study on the day of lung transplant

Subject Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from participation:

  • Patients listed for same-side lung re-transplantation
  • Patients listed for multiple organ transplantation including lung and any other organ
  • Patients listed for live donor lobar transplant
  • Patients with HIV, active Hepatitis B/C, or Burkholderia Cepacia
  • Patients not initially consented into the study prior to the time of lung transplant
  • Patients in the ICU at the time of initial lung offer requiring mechanical ventilation, ECMO or other Extracorporeal life support (ECLS).

Donor Lung Inclusion Criteria for EVLP Assessment:

The donor lung must meet at least one of the following criteria to proceed with EVLP:

  • At the time of the clinical evaluation, the donor PaO2/FiO2 6 hours
  • Donor age ≥ 55 years old
  • Study Center Investigator requires additional assessment ex vivo and/or extended preservation time

Donor Lung Exclusion Criteria for EVLP Assessment:

The donor lung is excluded from EVLP if at least one of the following criteria have been met:

  • The donor lung has confirmed pneumonia and/or persistent purulent secretions identified via bronchoscopy
  • Non-persistent purulent secretions that do not clear by hour 3 on EVLP
  • The donor lung has confirmed evidence of aspiration
  • The donor lung has significant mechanical lung injury or trauma
  • The cold ischemic time, starting at donor aortic cross clamp/ initial flush (CIT-1), required to transport the lung from the donor site to start of the EVLP procedure at SPONSOR's facility > 10 hours

EVLP Lung Inclusion Criteria for Transplantation:

The donor lung must meet each of the following conditions post-EVLP for transplant suitability consideration by the Study Center Investigator:

  • PvO2/FiO2 ≥ 350 mmHg at final EVLP evaluation time period
  • and 1 hour and ≤ 10 hours
  • the EVLP time > 3 hours and ≤ 6 hours
  • the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 6 hours for the first lung
  • the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 10 hours for the second lung
  • and Study Center Investigator deems lung function suitable for intended subject

EVLP Lung Exclusion Criteria for Transplantation:

The donor lung is excluded from transplant inclusion if at least one of the following criteria have been met:

  • PvO2/FiO2 10 hours
  • EVLP 6 hours
  • CIT-2 6 hours for first lung or > 10 hours for second lung
  • or Study Center investigator deems lung function unsuitable for intended subject
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02234128). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search